SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

 

For the month of: October 2016 Commission File Number: 001-35776

 

 

 

ACASTI PHARMA INC.

(Name of Registrant)

 

 

545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office )

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐             No  ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

 

 

 

This Report on Form 6-K including the exhibits hereto shall be deemed to be incorporated by reference into Acasti Pharma Inc.’s registration statement on Form S-8 (File No. 333-191383) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ACASTI PHARMA INC.
       
       
Date: October 11, 2016 By: /s/ Mario Paradis  
    Name: Mario Paradis  
    Title: VP & Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

EXHIBIT INDEX

 

 

Exhibit Description of Exhibit
99.1 Management Discussion and Analysis of the Financial Situation and Operating Results – Three and Six-Month Periods Ended August 31, 2016 and 2015
99.2 Interim Financial Statements for the Three-Month and Six-Month Periods Ended August 31, 2016 and 2015
99.3 Form 52-109F2 – Certification of Interim Filings - Full Certificate (CEO)
99.4 Form 52-109F2 – Certification of Interim Filings - Full Certificate (CFO)

 

 

 

 

 

 

 

 

 

 

 

Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Acasti Pharma Charts.
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Acasti Pharma Charts.